Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aptuit, Regulus in Strategic Provider Pact | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Aptuit, Regulus in Strategic Provider Pact

To provide a range of discovery, CMC and non-clinical services

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Aptuit and Regulus Therapeutics have entered a strategic provider relationship for a broad range of discovery and development services to support Regulus programs targeting microRNAs.


Dr. Goldman chief executive officer, Aptuit, said, “Aptuit provides high quality standalone and integrated solutions in the target to candidate, and candidate to IND phases of development. Our scientific expertise and high standards in chemistry and biology improve the probability of success. In addition, our scale and fully integrated end to end approach reduces timeline and costs, and are an excellent fit with Regulus focus on microRNA. We believe our support will allow Regulus to rapidly progress more programs in parallel.”

Dr. Timothy Wright, Regulus chief R&D officer, said, “Aptuit is recognized as a leading integrated service provider in the discovery and development space. We are delighted to engage Aptuit across multiple service areas to accelerate the progress of our most promising microRNA programs, achieving anticipated milestones and driving efficiency.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics